557 Early access protocol with abiraterone acetate for European patients with metastatic castration-resistant prostate cancer progressing after chemotherapy

European Urology Supplements ◽

10.1016/s1569-9056(15)60550-4 ◽

2015 ◽

Vol 14 (2) ◽

pp. e557-e557a

Author(s):

D. Castellano ◽

S. Bracarda ◽

M. Tucci ◽

O. Capoun ◽

V. Matveev ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Early Access ◽

Castration Resistant

Download Full-text

Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5061 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5061-5061

Author(s):

Cora N. Sternberg ◽

Gedske Daugaard ◽

Lajos Geczi ◽

Sebastien J. Hotte ◽

Paul N. Mainwaring ◽

...

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Early Access ◽

Castration Resistant

Download Full-text

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70417-6 ◽

2014 ◽

Vol 15 (11) ◽

pp. 1263-1268 ◽

Author(s):

Cora N Sternberg ◽

Daniel Castellano ◽

Gedske Daugaard ◽

Lajos Géczi ◽

Sebastien J Hotte ◽

...

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Early Access ◽

Castration Resistant

Download Full-text

Analysis of European Patients Enrolled in a Global Early Access Protocol with Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdu336.29 ◽

2014 ◽

Vol 25 ◽

pp. iv269 ◽

Author(s):

D. Castellano ◽

S. Bracarda ◽

M. Tucci ◽

O. Capoun ◽

V. Matveev ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Early Access ◽

Castration Resistant

Download Full-text

Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP)

European Urology Supplements ◽

10.1016/s1569-9056(17)30124-0 ◽

2017 ◽

Vol 16 (3) ◽

pp. e93-e94 ◽

Author(s):

F. Saad ◽

D. Heinrich ◽

S. Gillessen ◽

J. O’Sullivan ◽

J. Carles ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Early Access ◽

Castration Resistant ◽

Concurrent Use ◽

Download Full-text

Expanded access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer post-chemotherapy – results in Czech Republic

European Urology Supplements ◽

10.1016/s1569-9056(16)30243-3 ◽

2016 ◽

Vol 15 (11) ◽

pp. e1394

Author(s):

T. Hradec ◽

O. Capoun ◽

R. Sobotka ◽

M. Pesl ◽

V. Soukup ◽

...

Keyword(s):

Prostate Cancer ◽

Czech Republic ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Expanded Access ◽

Castration Resistant

Download Full-text

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate

Case Medical Research ◽

10.31525/ct1-nct04158245 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.793494158 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717999366.793474668 ◽

2013 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Antitumour Activity ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

A Rapid, Direct and Validated HPLC- Fluorescence Method for the Quantification of Abiraterone and Abiraterone Acetate in Urine and Serum Samples from Patients with Castration- Resistant Prostate Cancer

Current Pharmaceutical Analysis ◽

10.2174/1573412913666170213152002 ◽

2018 ◽

Vol 14 (3) ◽

pp. 233-238 ◽

Author(s):

Juana Rodriguez ◽

Gregorio Castaneda ◽

Isabel Lizcano ◽

Jose C. Villa

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Fluorescence Method ◽

Castration Resistant Prostate Cancer ◽

Serum Samples ◽

Castration Resistant ◽

Urine And Serum

Download Full-text

Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer

Current Medical Research and Opinion ◽

10.1080/03007995.2021.1888704 ◽

2021 ◽

Vol 37 (4) ◽

pp. 635-642

Author(s):

Stephen J. Freedland ◽

Sophia Li ◽

Dominic Pilon ◽

Rachel H. Bhak ◽

Sahil Narkhede ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Psa Progression

Download Full-text